Ren Duo Biology (688193.SH) disclosed its semi-annual report for 2024, with the company achieving revenue of 86.6802 million yuan, an increase of 8.31% year-on-year. The net profit attributable to shareholders of the listed company was 4.3308 million yuan, reversing the loss and turning into profit. The net loss attributable to shareholders of the listed company after deducting non-recurring gains and losses was 0.1434 million yuan. The basic earnings per share was 0.12 yuan/share. It is proposed to distribute a cash dividend of 1.00 yuan (including tax) per 10 shares.